New Retina Radio by Eyetube: Recent Episodes
Eyetube
What are the first steps retina specialists should take when a patient presents with postoperative inflammation? Host John Kitchens, MD, is joined by panelists Lisa Faia, MD, and Daniel Kiernan, MD, to debut the NRR miniseries "New Approaches to Chronic Postoperative Inflammation." They review which initial evaluation steps are most useful, discuss the wide range of preventive and treatment strategies, and offer pearls to clinicians who are managing postoperative inflammation.
As we enter the therapeutic era of geographic atrophy, imaging the disease is more important than ever. How are retina specialists navigating this new clinical dynamic? Moderator Rishi P. Singh, MD, is joined by Roger A. Goldberg, MD, MBA; Mrinali Gupta, MD; and Katherine Talcott, MD, as they examine which imaging modalities are best suited for busy clinics, discuss how software can facilitate longitudinal imaging tracking, and review which imaging reports are most conducive to patient education. This episode is sponsored by ZEISS.
New Retina Radio was at ASRS 2023 to cover the stories you may have missed. How often do patients return to the clinic on time for anti-VEGF injections? Christina Y. Weng, MD, MBA, and her team explored how often patients missed scheduled appointments, by how much, and whether missing appointments affected patient outcomes. And Nikolas JS London, MD, joined us in our mobile studio in Seattle to tell us about anatomic outcomes in wet AMD patients after faricimab (Vabysmo, Genentech/Roche) treatment. This is episode 1 of 2 covering the 2023 ASRS Annual Meeting. Keep an eye on your feed for episode 2.
How often did human graders agree with software designed to detect and quantify retinal fluid in wet AMD patients using a home OCT prototype? Moderator Sabin Dang, MD, is joined by panelists Lediana Goduni, MD, and Prethy Rao, MD, MPH, to examine how reliable such software was in a prospective observational study. After the break, the group speculates how these new data may affect retina doctors' comfort with home OCT and asks what is the minimum viable image quality required to trust home OCT imaging.
We know about long-term intravitreal injections that might slow the progression of geographic atrophy (GA). But could a gene therapy in the pipeline require fewer treatments and still yield results? Jeffrey Heier, MD, summarized an AAO presentation on the phase 1 data of JNJ-1887 (Janssen), a potential gene therapy for GA. Was it safe—and were there signs of efficacy? Michel Michaelides, BSc, MB,, BS MD(Res), FRCOphth, joined us to speak about a gene therapy targeting x-linked retinitis pigmentosa. With a phase 3 study for the drug AAV5-RPGR (Jannsen/MeiraGTx) already underway, what can we learn from earlier trial results?
Two biosimilars have been approved for retinal indications. What conclusions were drawn from the phase 3 studies that preceded their approval? Yasha Modi, MD, is joined by Kyle Kovacs, MD, and Priya Vakharia, MD, to review the ins and outs of biosimilarity, discuss the findings of two recent papers, and consider how use of biosimilars might affect future clinical practice in the United States.
Identifying systemic biomarkers indicating risk for age-related macular degeneration would be a game-changer. But how can we find those biomarkers? We spoke with Joan Miller, MD, whose work with the Harvard Retina Metabolomics Program focuses on identifying specific metabolites that might be useful in real-world practice. Also, Yannek Leiderman, MD, PhD, stopped by to fill us in on the state of artificial intelligence (AI) in the OR. How far away are surgeons from interacting in real time with AI?
Phase 3 data evaluating the biosimilarity of a new biosimilar (Xlucane, Xbrane Biopharma) referencing ranibizumab (Lucentis, Genentech) has been completed. What were the results? Anat Loewenstein, MD, joined New Retina Radio to walk us through the results of the XPLORE study. And Ramanath Bhandari, MD, summarized his presentation on the TRUCKEE study, a real-world evaluation of the performance of faricimab (Vabysmo, Genentech/Roche). What do the most recent updates tell us about practice patterns and patient response?
Researchers in the second pivotal study evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio) for the treatment of geographic atrophy have released 1-year results. New Retina Radio spoke with Arshad Khanani, MD, MS, about the GATHER2 study findings. How did the study results compare to the GATHER1 conclusions—and might the company move forward with a regulatory filing?
What is the effect of laser prophylaxis in patients with Stickler Syndrome, and just how effective are buckles in patients with GRT detachments? Yoshi Yonekawa, MD, PhD, is joined by Peter Campbell, MD; Karen Jeng-Miller, MD; and Prethy Rao, MD, to review two recent contributions to the literature, during which they probe the papers' findings and explore their limitations.
What changed in the most recent iteration of the International Classification of Retinopathy of Prematurity? And what do new data tell us about how ROP patients fare in adulthood? To find out, Yoshi Yonekawa, MD, PhD, is joined by Peter Campbell, MD; Karen Jeng-Miller, MD; and Prethy Rao, MD, to break down the latest literature, examine the papers' limitations, and offer pearls for surgical management of adults with history of ROP.
Can a quantitative analysis of OCT images detect early diabetic retinopathy in patients without symptoms? New Retina Radio spoke with Jennifer Lim, MD, whose research team sought to learn whether imaging analyses of photoreceptor length and reflectivity parameters could serve as a biomarker for disease detection. We also sat down with Lejla Vajzovic, MD, who shared data on a pair of phase 1 studies assessing the safety and efficacy of two gene therapies for achromatopsia. One of those two drugs will be going on for further study. Which one? Stick with us to find out.
Retina specialists may wish to turn to the literature to learn more about multifocal, indolent, nonprogressive choroidal lesions. Let the New Retina Radio Journal Club with VBS help you out. Moderator Kyle Kovacs, MD, is joined by Cynthia Qian, MD, and David Xu, MD, to review two recent papers on this atypical presentation.
Was treat-and-extend faricimab (Vabysmo, Genentech) an effective means of controlling DME in the YOSEMITE and RHINE studies? New Retina Radio spoke with John Kitchens, MD, whose ASRS presentation reviewed results from a pair of phase 3 studies that assessed, in part, 12- and 16-week dosing intervals of faricimab in patients with DME. Also joining us is Michael Allingham, MD, PhD. He shared results from the phase 2b ZETA-1 study, which examined the safety and efficacy of APX3330 (Ocuphire Pharma), an oral medication for DR. What promise might this treatment hold? Tune in to learn more. This editorially independent podcast is supported with advertising.
Treat-and-extend regimens has been used for thousands of wet AMD patients. How does brolucizumab (Beovu, Novartis) stack up when compared with aflibercept (Eylea, Regeneron) in a matched treat-and-extend study? New Retina Radio spoke with Carl Regillo, MD, a member of the TALON study group, which sought to find out if brolucizumab was superior to aflibercept for extending treatment intervals in wet AMD patients. We also spoke with Carl Danzig, MD, whose work on the TRUCKEE study illuminates real-world treatment dynamics when it comes to the use of faricimab (Vabysmo, Genentech) in wet AMD treatment. How are patients responding in the real world?
How might two recent contributions to the literature deepen our understanding of recurrent rhegmatogenous retinal detachment (RRD)? To find out, moderator Kyle Kovacs, MD, is joined by panelists Cynthia Qian, MD, and David Xu, MD, to review a pair of papers on the topic. After the break, the group tackles tamponade selection and use of scleral buckles in patients with RRD, and discusses tactics for bringing a patient back to the OR if RRD recurs. This editorially independent podcast is supported with advertising.
In this episode, John W. Kitchens, MD, speaks with Steve Charles, MD, FACS, FICS, FASRS, a vitreoretinal surgeon and founder of the Charles Retina Institute in Germantown, Tennessee, as well as clinical professor of ophthalmology at the University of Tennessee in Memphis. Known to many as the architect behind the ACCURUS and CONSTELLATION from Alcon, his career is wildly impressive, but Dr. Kitchens finds his life and career history even more fascinating.
This podcast is editorially independent.
What are the latest findings regarding pentosan poloysulfate maculopathy (PPM)? Moderator Basil Williams, MD, invites panelists Karen Jeng-Miller, MD, MPH; M. Ali Khan, MD; and Katherine Talcott, MD, to review two recent publications seeking to better characterize the condition After the break, the discussion turns to the utility of imaging modalities in PPM management and an exploration into hospital-based policies that might lead to earlier detection of PPM in patients undergoing a new course of pentosan polysulfate sodium therapy.
Could an 8-mg dose intensify the therapeutic effect of aflibercept (Eylea, Regeneron) in patients with wet AMD? The phase 2 CANDELA study sought to explore the safety and efficacy of high-dose aflibercept in this patient population. What did Dave Brown, MD, and his research colleagues observe?
And 96-week data from ARCHWAY are in. Did the complete study, which reached its primary endpoint after 40 weeks, reveal new data that could affect clinical decision-making when it comes to real-world use of the Port Delivery System with Ranibizumab (Susvimo, Genentech)? Hear our interview with Robert Mittra, MD, to find out.
This editorially independent podcast is supported with advertising.
Could RPE cell replacement therapy be the future of GA treatments? Retina Today’s Chief Medical Editor Allen C. Ho, MD, joined us to discuss observations from a phase 1/2a study evaluating the safety and efficacy of OpRegen (Lineage Cell Therapeutics), a suspension of allogenic RPE cells implanted in the subretinal space. How well was this therapy tolerated, and were there any signs of vision improvement? Elsewhere in the GA pipeline, researchers are exploring whether the gene therapy GT005 (Gyroscope Therapeutics) might be a safe and effective one-time treatment for GA via upregulation of complement factor I. How does complement factor I affect the course of GA, and what are the latest data from a phase 1/2 study? Check out this episode to hear on conversation on that topic with Jared Nielsen, MD, MBA.
This podcast is editorially independent, supported with advertising.
Could photobiomodulation soon be a therapeutic option for patients with dry AMD? Researchers in the LIGHTSITE III study are working toward finding out. We spoke with Marion Munk, MD, PhD, about the details from a study that evaluated the Valeda Light Delivery System (LumiThera) in patients with dry AMD. Were patients able to safely realize any improvement to visual function?
And we checked in with Roger Goldberg, MD, MBA, who detailed the 18-month findings of the DERBY and OAKS studies, a pair of phase 3 clinical trials evaluating the safety and efficacy of pegcetacoplan (APL-2, Apellis Pharmaceuticals) in patients with geographic atrophy. The studies’ primary endpoint was at 1 year. What did they find after an additional 6 months? Stick here to find out.
Anti-VEGF therapy has been a game changer for patients with AMD; now, the treatment toolbox is getting an overhaul with two new approvals and, hopefully, more on the way. Allen C. Ho, MD, sat down with Robyn Guymer AM, MBBS, PhD, FRANZCO, FAHMS; Charles C. Wykoff, MD, PhD; and Diana V. Do, MD, to discuss how these new treatments are going to change clinical practice and how to educate patients on the pros and cons of each option.
How has reimbursement for common vitreoretinal procedures changed from 2011 to 2020? To find out, moderator Eric Nudleman, MD, PhD, hears from panelists John Miller, MD; Thanos Papakostas, MD; and Priya Vakharia, MD, as they discuss a recent piece on the topic published in the journal Ophthalmology. After reviewing the findings, the panel discusses the implications for reduced reimbursement in an era of improved efficiency and asks whether future innovation will allow patients to receive the same level of care even as reimbursement declines.
Do the demographics of patients enrolled in clinical trials accurately reflect the patient populations their drugs intend to treat? Moderator Basil Williams, MD, is joined by panelists Karen Jeng-Miller, MD, MPH; M. Ali Khan, MD, and Katherine Talcott, MD, to summarize a pair of papers exploring this topic. After summarizing the papers' findings, the group reviews a phase 4 trial seeking to enroll underrepresented patients and asks which barriers to enrollment may be linked to shortcomings in demographic diversity.
Pars plana vitrectomy (PPV) and pneumatic retinopexy (PnR) are both commonly employed to repair rhegmatogenous retinal detachment (RRD). What does the literature have to say about the safety and outcomes of these two procedures? Moderator Eric Nudleman, MD, PhD, asks panelists John Miller, MD; Thanos Papakostas, MD; and Priya Vakharia, MD, to break down the PIVOT and ALIGN studies, both of which were recently published in the journal Ophthalmology Retina. What were these studies’ findings—and how accurately do they reflect clinical experience?
Have innovations in therapy actually led to a paradigm shift when it comes to encountering patients with newly diagnosed wet AMD? In the season finale of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, is joined by panelists Lejla Vajzovic, MD, and Joseph M. Coney, MD, to review strategies for treating new wet AMD patients, to discuss where new technologies fit into a treatment algorithm, and to examine the best time to switch patients to a new therapeutic option. After the break, Dr. Khanani updates the panel on a patient case shared in previous seasons of this series, which involves a patient with a 12-year treatment history who experienced significant vision loss following a change in therapy. How did Dr. Khanani manage the case—and what happened after inflammation was brought under control? This editorially independent podcast is supported with advertising.
How do retina specialists decide which wet AMD patients are best suited for extended duration therapy and which patients should continue with more traditional intervention? In the second episode of this season of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, asks Lejla Vajzovic, MD, and Joseph M. Coney, MD, about which factors they weigh most heavily when determining if a patient could be a good candidate for a change in treatment strategy, and discuss how gene therapy may play a role in wet AMD treatment. After the break, Dr. Vajzovic reviews the case of a patient who has undergone treatment with three different anti-VEGF agents. Why and when did she switch this patient to a different therapy?
This editorially independent podcast is supported with advertising.
How have the most recent advances in wet AMD therapy changed the treatment landscape for clinicians? In this debut episode of the third season of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, is joined by Lejla Vajzovic, MD, and Joseph M. Coney, MD, for a discussion about choosing patients who are best suited for the recently approved therapies, and for a preview of how biosimilars could affect treatment decisions. After the break, Dr. Coney shares the case of a patient whose need to extend treatment intervals was addressed by switching to a new anti-VEGF agent. This editorially independent podcast is supported with advertising.
This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again. Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD, to tell the latest chapter of anti-VEGF's biography. This editorially independent podcast is supported with advertising.
New Retina Radio continues its biography of anti-VEGF. John D. Pitcher III, MD, picks up the story where we left off: in a world where pegaptanib was the only intravitreal injection approved for treating wet AMD. But a deep dive into the literature and a few calculations on the back of a napkin are about to change retina practice forever. Guests in this episode include Bob Avery, MD; Dave Brown, MD; Anne Fung, MD; Jeffrey Heier, MD; Andrew Moshfeghi, MD, MBA; Kirk Packo, MD; and Philip Rosenfeld, MD, PhD. This editorially independent podcast is supported with advertising.
Recently, the first refillable, intraocular device that enables continuous delivery of therapy was FDA approved for nAMD. John Kitchens, MD sits down with one of the investigators, Dante Pieramici, MD, to learn more about his experiences with the clinical development program and this innovative drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.
In this roundtable moderated by Allen C. Ho, MD, and Robert L. Avery, MD, experts discuss the frustration of postoperative proliferative vitreoretinopathy and strategies to minimize its incidence in the clinic. Panelists include Dean Eliott, MD; Avni P. Finn, MD, MBA; Ajay Kuriyan, MD, MS; and M. Ali Khan, MD. This podcast is editorially independent.
Many young retina specialists have always known retina as an anti-VEGF world. But how did this happen? John D. Pitcher III, MD, joins Scott and Ranna in studio to deliver the first part of the tale of anti-VEGF in retina, taking the story back to the 1970s to tell the story of the discovery of VEGF, the creation of pegaptanib, and the struggles that early anti-VEGF encountered in retina. There are a lot of guests for this one, but the major players for this episode are Tony Adamis, MD; Bob Avery, MD; Jeff Heier, MD; and Kirk Packo, MD. This editorially independent podcast is supported with advertising.
Innovation often drives surgeons to adopt new techniques and surgical approaches. Join John Kitchens, MD, Carl Awh, MD, and Aleksandra Rachitskaya, MD as they discuss their experiences with a new refillable, intraocular device that enables continuous delivery of therapy for patients with nAMD. Listen as they provide their insights on learning the implant and refill- exchange procedures as well as their perspectives on the training program for the device. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.
In the culmination of this case-based series discussing who is best suited for which types of wet AMD therapy, John Kitchens, MD, invites Murtaza Adam, MD, and Aleksandra Rachitskaya, MD, to the program to showcase two real-world patient files. After they are done with case discussions, Drs. Adam, Kitchens, and Rachitskaya examine how patient lifestyle details may affect treatment strategies. This editorially independent podcast is supported with advertising.
In the second installment of this ongoing series covering wet AMD, Lisa Faia, MD, and Sumit Sharma, MD, submit to host John Kitchens, MD, a set of real-world patient cases in which treatment challenges necessitated a change in therapy. After revealing which treatment option is best suited for their respective patients, Drs. Faia and Sharma parse which patient types are eligible for long-duration treatment and which types are better matched for more traditional approaches. This editorially independent podcast is supported with advertising.
Changes to the uveitis treatment landscape after years of stagnation warrant a reset on what is approved, what the latest data are, and which developments are in the pipeline. Glenn Jaffe, MD, summarized his state of the union on uveitis therapy, reviewing data from the most recently approved innovations in the field. Nicole Koulisis, MD, joins the program to review data on ocular injuries linked to social unrest in the summer of 2020. What were the causes linked to ocular injuries, how severely was vision affected, and what were final outcomes for these patients? This editorially independent podcast is supported with advertising.
In the first of this three-part series reviewing topics in wet AMD, Carl Regillo, MD, and Adrienne Scott, MD, join moderator John Kitchens, MD, to submit a pair of real-world patient cases illustrating how the need to reduce the burden of care may drive treatment decisions in patients with wet AMD. After they reveal how they managed their respective patient cases, Drs. Regillo and Scott join Dr. Kitchens for a review of how the latest innovations in retina could improve patients’ lives by alleviating treatment burden. This editorially independent podcast is supported with advertising.
As more data are published regarding medical intervention for macular hole closure, retina specialists want to know which patients are best suited for this approach and in which cases it may be most effective. Christina Weng, MD, MBA, invites Brian Do, MD; Mrinali Gupta, MD; and Dimitra Skondra, MD, PhD, to summarize and respond to a pair of retrospective case series that explored the safety and efficacy of drop regimens for macular hole closure. The group discusses the papers’ findings and comments on their own experience with medical management of macular holes. This editorially independent podcast is supported with advertising.
In this roundtable moderated by Allen C. Ho, MD, IRD experts discuss their experiences treating patients with voretigene neparvovec (Luxturna, Spark), tips and tricks for subretinal delivery, and the nuances of genetic testing. Participants include Mark E. Pennesi, MD, PhD; Jacque L. Duncan, MD; Andreas Lauer, MD; Aaron Nagiel, MD, PhD; and Artur V. Cideciyan, PhD. To read the article, click here. This podcast is editorially independent.
Extending treatment duration in patients with DME whose disease is responsive to steroid therapy could be instrumental in ensuring that visual disruption is kept at a minimum. How might the 3-year results from the PALADIN study guide treatment in the near future? Michael Singer, MD, reviewed data from a phase 4, 3-year, real-world study of patients whose DME was managed with fluocinolone acetonide 0.19 mg implant (Iluvien, Alimera Sciences). And NRR sat down with R.V. Paul Chan, MD, MSc, MBA, who summarized updates to ROP therapy as outlined in the 3rd edition of the International Classification of Retinopathy of Prematurity. What are the updates, and what spurred the ICROP to make them? Tune in to find out. This editorially independent podcast is supported with advertising.
Is a technology that inhibits tyrosine kinase and shows activity against all isoforms of VEGF and placental growth factor the future of wet AMD therapy? Data from the DAVIO study, which were shared at the 2021 AAO Annual meeting late-breakers session, could be of interest. David Boyer, MD, discussed the drug design of EYP-1901 (EyePoint Pharmaceuticals) and summarized the findings of the phase 1 DAVIO study, which examined the drug’s use in wet AMD patients. NRR also invited Firas Rahhal, MD, to review the safety and efficacy findings of the phase 3 NORSE-2 trial, which explored use of an ocular formation of bevacizumab (bevacizumab-vikg, Outlook Therapeutics) in patients with wet AMD. This editorially independent podcast is supported with advertising.
The biosimilars are coming—and studies about them are starting to fill the literature. One such study is the COLUMBUS-AMD study, which evaluated the clinical equivalence of FYB201 to ranibizumab for the treatment of wet AMD. Aleksandra Rachitskaya, MD, breaks down the study with Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD. The group expands on what biosimilars are and asks what the future of retina could look like if biosimilars are approved for clinical use. This editorially independent podcast is supported with advertising.
Can anti-VEGF agents act as effective prophylactic treatment for diabetic patients with a high risk of developing diabetic eye disease? Data from the Protocol W’s 2-year timepoint shared at the 2021 AAO Annual meeting might provide some answers on that question. Raj Maturi, MD, joined New Retina Radio to discuss his podium presentation on the topic. New Retina Radio also invited Usha Chakravarthy, MD, PhD, to the program to outline her presentation on the secondary endpoints of the EDNA study. What was found when a team closely monitored patients for progression of unilateral to bilateral wet AMD? Join us on this episode to hear the details from these two presentations. This editorially independent podcast is supported with advertising.
Knowing at which point in the course of disease progression a drug for geographic atrophy could be most effective may be key to unlocking a treatment paradigm if a drug is approved. What late-breaking data presented at the 2021 AAO annual meeting could help inform retina’s eventual strategy to treat GA? New Retina Radio spoke with David Lally, MD, about his presentation on a post hoc analysis of the GATHER1 study to learn more about how GA patients who received avacincaptad pegol (Zimura, IVERIC bio) progressed from nascent disease to more advanced disease. We also heard from Veeral Sheth, MD, MBA, about the phase 2b ALTISSIMO study, which explored the use of GB-102 (Graybug Vision) for the treatment of wet AMD. Just how long might a drug administered only twice a year provide relief to wet AMD patients? Stay with us to find out. This editorially independent podcast is supported with advertising.
The treatment landscape for nAMD has expanded to include a refillable, intraocular device that continuously delivers therapy. What was the inspiration behind this new treatment approach? John Kitchens, MD is joined by inventor Eugene de Juan, MD and physician-scientist Tony Adamis, MD to discuss the device and the innovative technology behind its development. During this podcast, they reflect on how their careers and contributions from others in the field led to the drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.
How do the latest data and treatment guidelines inform treatment strategies for retinopathy of prematurity (ROP) among European and Latin American retina specialists? Moderator Prof. Andreas Stahl (Germany) and panelist Dr. Maria Ana Martinez-Castellanos (Mexico) discuss the dynamics of patient care in their respective regions, and are joined by Silke Mader from the European Foundation for the Care of Newborn Infants to hear about the organization’s initiatives related to ROP. This editorially independent podcast is supported with advertising.
In part 2 of this special podcast interview with John W. Kitchens, MD, and Kirk Packo, MD, FACS, they dive into Dr. Packo's involvement in the creation of AAO subspecialty day, his passion for honoring the history of retina, and his assistance in advocating for vitreoretinal surgery improvements. This podcast is editorially independent.
In this new podcast episode, John W. Kitchens, MD, interviews Kirk Packo, MD, FACS, around his triumphant career and his decision to retire from practicing medicine following an unexpected diagnosis. In part 1 of 2, Dr. Packo describes his early career goals, his experience with residency matching, his background in acting and directing, and his passion for educating. This podcast is editorially independent.
The pipeline in retina is bursting! Which datasets shared at the ASRS 2021 meeting provided insights into the future of retina? Mark Barakat, MD, joins the podcast to discuss topline results from a study examining the suprachoroidal delivery of RGX-314 (RegenxBio). And Nancy Holekamp, MD, stops by to educate us on the potential for targeting C1q in the complement cascade in patients with geographic atrophy. What’s the latest with the phase 2 ARCHER study? Find out on this episode. This editorially independent podcast is supported with advertising.
The age of big data allows researchers to uncover how real-world patients with geographic atrophy (GA) behave. What did a deep dive into the IRIS Registry find? We spoke with Durga Borkar, MD, about her research team’s findings on which GA patients are most at risk to being lost to follow-up, which may inform treatment strategies once a drug is approved. And we sat down with M. Ali Khan, MD, whose meta-analysis of RISE/RIDE and three DRCR Retina Network studies explored possible visual outcomes gaps in Black and White patients with diabetic eye disease. This editorially independent podcast is supported with advertising.
We may be on the cusp of the next great era of wet AMD therapy. Which phase 3 data will guide physician decision-making if new technologies are approved by regulatory bodies? Chirag Jhaveri, MD, spoke with New Retina Radio about anatomic data collected in the phase 3 ARCHWAY study. How did patients who received the Port Delivery System with Ranibizumab (PDS, Genentech) differ from those on monthly ranibizumab (Lucentis, Genentech) in terms of fluctuation in central subfield thickness? And as FDA weighs the possible approval of faricimab for the treatment of wet AMD, we hear from Karl Csaky, MD, PhD, about the safety, efficacy, and durability of the drug for wet AMD in the TENAYA and LUCERNE studies. This editorially independent podcast is supported with advertising.
How can retina surgeons work with optometrists to create a framework that best manages the cases of patients with vitreous opacities? To answer this question, John Kitchens, MD, turns to Tarek Hassan, MD, and Walt Whitley, OD, MBA. The panel discusses how collaboration can transition patients smoothly to surgical consultation, the anatomy of a referral, and if some patients are better suited for surgery than others. This editorially independent podcast is supported with advertising.
Cytomegalovirus (CMV) retinitis continues to challenge retina specialists. Could use of CMV-specific cytotoxic T lymphocytes be an effective strategy in some patients? And if so, in whom? To answer these questions, Christina Weng, MD, MBA, is joined by study author Mrinali Gupta, MD, and panelists Brian Do, MD, and Dimitra Skondra, MD, PhD. During their discussion, we hear about the structure and findings of the study and learn about how these new data may affect treatment algorithms for patients with newly diagnosed CMV retinitis. This editorially independent podcast is supported with advertising.
In the next installment of the New Retina Radio miniseries "International Perspectives," moderator Jennifer Arnold (Australia) in joined by panelists Ramin Tadayoni (France) and Armin Wolf (Germany) to discuss the history and contemporary trends of RVO therapy. This editorially independent podcast is supported with advertising.
It isn't often that anterior segment and posterior segment surgeons discuss surgery. New Retina Radio, in a crossover episode with CRST: The Podcast, is changing that by initiating a conversation about surgery for vitreous opacities. John Kitchens, MD, invites retina specialist Maria Berrocal, MD, and anterior segment surgeon Elizabeth Yeu, MD, to chat surgical pearls, patient management tactics, and whether premium IOLs are exacerbating vitreous opacities. Stick around at the end of the episode for some compelling conversation that our editors salvaged from the cutting room floor. This editorially independent podcast is supported with advertising.
As retina inches closer to a therapy that is safe and effective for the treatment of GA in the presence of dry AMD, the VBS Journal Club meets to review a pair of papers on a pair of pipeline treatments undergoing phase 3 evaluations. Aleksandra Rachitskaya, MD, is joined by Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD, to review phase 2/3 GATHER1 study, which is evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio). They also discuss a post hoc evaluation of the phase 2 FILLY study to determine which factors may be linked to the development of exudative AMD in some study patients after treatment with pegcetacoplan (Apellis), which is underdoing phase 3 investigation in the DERBY and OAKS studies. This editorially independent podcast is supported with advertising.
Safety will ultimately drive decision-making for patients with wet AMD. What are the latest safety data in the MERLIN, ARCHWAY, OPTIC, RGX-314, and TENAYA/LUCERNE trials? Moderator Arshad M. Khanani, MD, MA (United States), and panelists Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), sift through the latest safety data to determine how concerns about safety could shape the future of wet AMD therapy. This editorially independent podcast is supported with advertising.
Perspectives regarding surgery for vitreous opacities (VOs) have shifted in the past several years. How have innovations in surgical instrumentation, visualization, and IOL technology changed how surgeons approach VOs? John Kitchens, MD, sits down with S.K. Steven Houston III, MD, and Christina Weng, MD, MBA, to hear their perspectives on the modern state of VOs, learn about their surgical tactics, and establish how they determine when to send patients to surgery. This editorially independent podcast is supported with advertising.
The pipeline of wet AMD treatments is inspiring. What can retina specialists around the world expect when it comes to wet AMD therapy candidates KSI-301 (Kodiak Sciences), RGX-314 (RegenxBio), and ADVM-022 (Adverum Biotechnologies)? Join moderator Arshad M. Khanani, MD, MA (United States), and panelists Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), as they review early-phase data from some of the possible wet AMD drugs of the future. This editorially independent podcast is supported with advertising.
In this opening installment of the New Retina Radio miniseries "International Perspectives," moderator Patricio Schlottmann (Argentina) sits down with panelists Catherine Creuzot-Garcher (France) and Adnan Tufail (United Kingdom) to review their strategies for treating patients with diabetic macular edema. The group discusses government regulations regarding the use of particular therapies and reviews why, in many cases, anti-VEGF therapy is the most effective therapeutic option. This editorially independent podcast is supported with advertising.
If new treatment options for wet AMD are approved for treatment, retina specialists will have even more options to switch patients to a new therapy. Which drug candidates have phase 3 data and real-world data that could point toward upcoming action by regulatory bodies? Arshad M. Khanani, MD, MA (United States), convenes an international panel comprised of Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), to review data related to brolucizumab (Beovu, Novartis), the Port Delivery System with Ranibizumab (Genentech), and faricimab (Roche). This editorially independent podcast is supported with advertising.
As the threat of COVID-19 subsides, scientists are working to make sense of the information that was gathered during the pandemic. Caroline Baumal, MD, asks M. Ali Khan, MD; Vlad Matei, MD; and Christina Weng, MD, MBA, to tackle two papers that analyze data collected during this time. First, they address the strengths and limits of a paper from the infectious disease realm that used history of AMD as a marker for complement inhibition in patients with COVID-19. Then, they parse the details of an article reviewing how real-world high-frequency patients with wet AMD fared when treatment intervals were increased during the height of the pandemic. This editorially independent podcast is supported with advertising.
Retina specialists around the world aim to reduce treatment burden while maximizing therapeutic outcomes in patients. How do global experts decide when to switch and to which therapy? Arshad M. Khanani, MD, MA (United States), is joined by Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), to discuss tactics for moving wet AMD patients to new therapies or regimens. Also, Prof. Garweg shares a case of a patient who benefited from a new treatment option approved for wet AMD. This editorially independent podcast is supported with advertising.
In the third episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Carl Awh, MD, and Dante Pieramici, MD, about surgical options for neovascular AMD and how they might be applied in clinical practice. Although some of these options are still in the later stages of development, the panel looks forward to options that may truly change the treatment paradigm for the better. Click here to listen to this and other episodes in this series. This editorially independent podcast is supported with advertising.
In this roundtable moderated by Allen C. Ho, MD, experts in gene therapy discuss the latest data, clinical trial hurdles, and the promise these programs hold for patients being treated for wet AMD. Participants include Robert L. Avery, MD; Peter Campochiaro, MD, PhD; Jeffrey S. Heier, MD; Szilárd Kiss, MD; and Charles Wykoff, MD, PhD. This editorially independent podcast is supported with advertising.
Masks are effective in curbing transmission of COVID-19. But could they also direct bacteria toward the ocular region? Yoshi Yonekawa, MD, hears from two primary study investigators—Ajay Kuriyan, MD, and Jonathan Chang, MD—about their newly published studies, and invites Paula Pecen, MD, to evaluate the studies' designs, findings, and clinical relevance. After the break, all four doctors compare the two papers and review their respective masking protocols. This editorially independent podcast is supported with advertising.
In the second episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Jennifer Lim, MD, and Charlie Wykoff, MD, PhD, about the challenges inherent to finding the best retreatment interval for each patient. The panel also shares thoughts on how clinical trials could be structured to deliver data that would help clinicians understand durability of existing and new and novel treatment options. Click here to listen to this and other episodes in this series. This editorially independent podcast is supported with advertising.
How effective is the use of autologous retina transplant for the treatment of macular holes? Caroline Baumal, MD, moderates a panel comprised of M. Ali Khan, MD; Vlad Matei, MD; and Christina Weng, MD, MBA, during which they summarize and comment on a recent research paper on this subject published in the journal Ophthalmology. After the break, the group discusses which cases are best suited for this technique and discuss tactics for teaching fellows how to perform autologous retinal transplant. This editorially independent podcast is supported with advertising.
In this episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Margaret Chang, MD, and David Eichenbaum, MD, about the consequences of missed injection appointments and less than ideal adherence to monitoring among patients with neovascular AMD. Listen in as the experts discuss some of the challenges inherent to treating patients in real-world practice and share insights on strategies for encouraging adherence. This editorially independent podcast is supported with advertising.
C3 is a possible target in patients with geographic atrophy. What do the latest data from ARVO tell us about the safety and tolerability of NGM621, a drug aimed at that point in the complement cascade? David Eichenbaum, MD, sat down with New Retina Radio to review the results of a phase 1 study evaluating NGM621 in patients with geographic atrophy. Also, Amy Schefler, MD joined the show to review the design, methods, and rationale for the creation of the COOG2, or the second iteration of the Collaborative Ocular Oncology Group. How might the COOG help advance treatment for ocular cancer? This editorially independent podcast is supported with advertising.
18-month results for GATHER1 look promising, but another pivotal study is still in the works. What else needs to happen for Zimura to become the first FDA-approved therapy for geographic atrophy? New Retina Radio spoke with Veeral Sheth, MD, about what he shared regarding the GATHER1 study at this year’s ARVO meeting.
We also spoke with Matthew Starr, MD, about his research on the development of CME following rhegmatogenous retinal detachment surgery. Could his findings help surgeons better understand the risk factors for complication after surgery? This editorially independent podcast is supported with advertising.
The phase 3 TENAYA and LUCERNE trials, which assessed the safety and efficacy of faricimab for wet AMD therapy, have wrapped up. What did the researchers learn? New Retina Radio spoke with Arshad Khanani, MD, MA, about his ARVO presentation on these trials. We also spoke with David Lally, MD, whose ARVO presentation adds new data to the great fluid debates in wet AMD. What did his research team uncover that can inform our understanding of fluid dynamics in these patients? This editorially independent podcast is supported with advertising.
Need a refresher on Protocol W, the latest study from the DRCR Retina Network? Yoshi Yonekawa, MD, invites VBS members Ajay Kuriyan, MD; Anton Orlin, MD; and Paula Pecen, MD, to review the data from Protocol W and to discuss how the study may change their practice patterns. This editorially independent podcast is supported with advertising.
In the second part of this two-part series on literature in retinal detachment surgery, moderator Jay Sridhar, MD, is joined by panelists Brian Do, MD; Sabin Dang, MD; and Avni Finn, MD, MBA, to discuss a pair of recently published reports. The panel reviews an article on the outcomes of primary RRD repair with extensive scleral-depressed vitreous and dynamic examination, as well as a report on 360º laser retinopexy during primary vitrectomy with or without scleral buckling for RRD. This editorially independent podcast is supported with advertising.
In the first part of this two-part series reviewing reports from the Primary Retinal Detachment Outcomes Study Group, moderator Jay Sridhar, MD, invites panelists Brian Do, MD; Sabin Dang, MD; and Avni Finn, MD, MBA, to dissect a trio of papers. They discuss the results of studies examining retinal detachment surgery outcomes in phakic and pseudophakic patients. After the break, the panel summarizes and reviews the findings from a report comparing vitrectomy alone to vitrectomy with scleral buckle for retinal detachment with inferior retinal breaks. This editorially independent podcast is supported with advertising.
Early phase data sets are one of the stars of the Angiogenesis, Exudation, and Degeneration annual meeting. Which presentations are worth a second look? John Kitchens, MD, is joined by Nadia Waheed, MD, and Charles Wykoff, MD, PhD, as they share data from their respective presentations showcased at this year’s meeting. After the break, Drs. Kitchens, Waheed, and Wykoff chat what these early phase data could mean for the future of retina care. This editorially independent podcast is supported with advertising.
Which upcoming therapies will extend duration for patients with wet AMD? John Kitchens, MD, sits down with Diana Do, MD, and Carl Regillo, MD, to hear about their presentations at this year’s Angiogenesis, Exudation, and Degeneration annual meeting. After the break, Drs. Kitchens, Do, and Regillo discuss how the future of wet AMD therapies may alter clinical care for patients undergoing treatment. This editorially independent podcast is supported with advertising.
Can OCT be used to detect areas at risk for GA progression in patients with intermediate AMD? Yoshihiro Yonekawa, MD, invites Marion Munk, MD, PhD; Lejla Vajzovic, MD; and David Xu, MD, to discuss a paper published by the AREDS2 Group on this topic. They explore the researchers' findings and discuss the clinical implications of the study's results. This editorially independent podcast is supported with advertising.
How close are retina specialists to offering an effective therapy for patients with geographic atrophy secondary to dry AMD? John Kitchens, MD, hears summaries of two talks from Pravin Dugel, MD, and SriniVas Sadda, MD, from this year’s Angiogenesis, Exudation, and Degeneration meeting. After the break, Dr. Kitchens moderates a discussion about the nuances of bringing treatments in this disease to patients. This editorially independent podcast is supported with advertising.
In this roundtable hosted by María H. Berrocal, MD, and Audina M. Berrocal, MD, new department chairs in retina share their journeys to leadership and how to move the needle on diversity in the field. Participants include Sophie J. Bakri, MD, MBA; R.V. Paul Chan, MD, MSc, MBA, FACS; and Shlomit Schaal, MD, PhD, MHCM. This editorially independent podcast is supported with advertising.
Aleksandra Rachitskaya, MD, moderates a panel comprised of Mrinali Gupta, MD; Eric Nudleman, MD, PhD; and Aris Thanos, MD, to review a study from the DRCR Retina Network that compared intravitreal aflibercept (Eylea, Regeneron) to vitrectomy with panretinal photocoagulation for the treatment of vitreous hemorrhage secondary to proliferative diabetic retinopathy. The group summarizes the study and weighs how its findings could affect clinical practice. This editorially independent podcast is supported with advertising.
Aleksandra Rachitskaya, MD, leads a discussion with Mrinali Gupta, MD; Eric Nudleman, MD, PhD; and Aris Thanos, MD, about the phase 2 LADDER study, which evaluated the Port Delivery System With Ranibizumab (Genentech) in patients with wet AMD. Listen to a summary of the study and a thorough discussion of its implications with this group of Vit-Buckle Society members. This editorially independent podcast is supported with advertising.
In this podcast, Prof. Richard Harrad (UK) joins Prof. Ben Thompson (Canada) and Prof. Ann Webber (Australia) for a discussion on the use of dichoptic therapy in the management of amblyopia. In this episode, we consider the limitations of the current clinical approach to amblyopia before discussing dichoptic therapy, a new and innovative technology with the potential to address some of the unmet needs in the management of this common condition. The faculty review the available evidence for dichoptic therapy, its potential benefits, the challenges associated with its use and how these might be overcome. This editorially independent podcast is supported with advertising.
In this podcast, Dr Peter Kaiser (USA) leads a conversation with Prof. James Wolffsohn (UK) and Dr Pearce Keane (UK) in which they explore the use of AI technology in clinical practice and how it may lead to changes in the management of patients. Considering both the front and the back of the eye, the faculty discuss current and potential future uses of AI in ophthalmology and optometry, the challenges associated with the development and integration of AI systems, and the benefits that may result from its use in eye care. This editorially independent podcast is supported with advertising.
Will data shared at AAO 2020 affect your clinical decision-making with wet AMD patients? Rishi Singh, MD, invites Justis Ehlers, MD, and Mark Gillies, MD, PhD, to review their presentations from AAO 2020 and discuss how clinical practice may be affected by their new information. Dr. Ehlers presented data on fluid volatility and the software used to measure it, and Dr. Gillies examined a 10-year data set of real-world wet AMD patients.
This editorially independent podcast is supported with advertising.
Join Dr. Rishi Singh (USA) as he speaks with Prof. Jennifer Arnold (Australia), Prof. Mark Gillies (Australia) and Dr. SriniVas Sadda (USA) about the role and importance of fluid in the management of retinal diseases. In this episode, we will look at the different fluid compartments and our current understanding of their relevance to neovascular AMD. We will discuss the learnings gained from the HARBOR and FLUID clinical trials and the Fight Retinal Blindness! project, and consider key questions such as whether fluid can be protective and which types of fluid need to be treated aggressively.
This editorially independent podcast is supported with advertising.
Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, review real-world data that compare widefield swept-source OCT angiography with ultra-widefield color fundus photography and fluorescein angiography for the detection disease activity in patients with diabetic retinopathy.
This editorially independent podcast is supported with advertising.
Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, discuss a retrospective study on the efficacy and safety of an intravitreal dexamethasone implant (Ozurdex, Allergan) in patients with diabetic macular edema. They review the top-line data and study design of this real-world report.
This editorially independent podcast is supported with advertising.
How will data shared at AAO 2020 impact clinical decision-making in wet AMD therapy? Rishi Singh, MD, is joined by Diana Do, MD, and Jeffrey Heier, MD, to review their talks from the AAO 2020 meeting and to see how their data might influence the day-to-day work of clinicians in retina. Dr. Do presented a meta-analysis comparing all anti-VEGF agents and regimens for the treatment of wet AMD, and Dr. Heier examined baseline patient characteristics in HAWK/HARRIER to have a better understanding of IOI events.
This editorially independent podcast is supported with advertising.
DRCR Retina Network Protocol AB compared aflibercept (Eylea, Regeneron) to PPV and PRP in patients with diabetic vitreous hemorrhage. DRCR Retina Network Vice Chair and Protocol AB chair Andrew Antoszyk, MD, joins NRR to review the study’s findings, which were presented at this year’s AAO Annual Meeting.
This editorially independent podcast is supported with advertising.
Tracking real-world data on geographic atrophy has been patchwork process—until now. Thanks to the AAO IRIS Registry, real-world information on eye diseases can be gathered and assessed. What was found in the IRIS Registry regarding GA, and how will it change the way you practice? Ehsan Rahimy, MD, outlines how he and his team identified patients and trends, and summarizes how he applied the group’s findings to his practice. Dr. Rahimy presented data from this discussion during this year’s AAO Annual Meeting Late Breakers session.
This editorially independent podcast is supported with advertising.
In 2021, E/M codes will undergo their most significant changes since 1997. How will these changes affect your billing and coding—and what processes can you put in place to get ahead of the game? AAO Coding and Practice Management Executive Joy Woodke informs us of the changes ahead, which were shared at this year’s AAO Annual Meeting.
This editorially independent podcast is supported with advertising.
The next generation of therapy for DME patients will require looking beyond the VEGF pathway. In the phase 2 BOULEVARD study, researchers are assessing the safety and efficacy of the angiopoietin-2 mediator faricimab (Roche/Genentech) for the treatment of DME. Could the angiopoietin pathway present a new option for patients? Karl Csaky, MD, PhD, sits down with NRR to review data from the study, which were shared at this year’s AAO Annual Meeting Late Breakers session.
This editorially independent podcast is supported with advertising.
Retinal arteriolar macroaneurysm (RAM) usually regresses spontaneously, but can lead to irreversible vision loss if regression does not occur. Could anti-VEGF therapy be an option for these patients? J. Fernando Arevalo, MD, PhD, joins NRR to discuss data from a study that asked that question. He presented the data at this year’s AAO Annual Meeting.
This editorially independent podcast is supported with advertising.
The burden of anti-VEGF therapy is particularly high in DME patients, many of whom are young, in the workforce, and unable to easily maintain monthly therapy. Could the antibody biopolymer conjugate KSI-301 (Kodiak Sciences) alleviate that burden while maintaining the outcomes experienced with anti-VEGF therapy? Arshad M. Khanani, MD, MA, shares the results of the phase 1B, long-term, multidose study that was presented at this year’s AAO Annual Meeting Late Breakers session.
This editorially independent podcast is supported with advertising.
In episode 2 of the NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data,” Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution?
This editorially independent podcast is supported with advertising.
NRR’s miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” wraps up with moderator Dr. Khanani and panelists Drs. Fuller, London, and Weng discussing safety data. How have safety considerations changed in the wet AMD treatment landscape, and how do clinicians balance the risks and rewards of switching to a new agent? Additionally, Dr. Khanani closes out the series with the case of a patient whose disease stopped responding after a decade of anti-VEGF therapy. Listen here to learn how he approached the case.
This editorially independent podcast is supported with advertising.
Arshad M. Khanani, MD, MA, leads a roundtable consisting of Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA, as they discuss the art of drug choice in wet AMD therapy. The panel discusses how and why they switch therapy in challenging wet AMD cases and reviews how the COVID-19 pandemic has factored into their treatment algorithms. Also, Dr. Fuller shares the case of a wet AMD patient whose waning response to traditional therapy required intervention with an intravitreal dexamethasone implant (Ozurdex, Allergan).
This editorially independent podcast is supported with advertising.
This NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” continues as Dr. Khanani and the roundtable participants Drs. Fuller, London, and Weng review the wet AMD pipeline with a focus on anti-Ang-2 therapy (faricimab, Roche/Genentech) and gene therapy (RGX-314, RegenxBio and ADVM-022, Adverum Biotechnologies). After the break, Dr. London shares the case of a patient with wet AMD who experienced a ceiling of response to anti-VEGF therapy. Did a switch to brolucizumab (Beovu, Novartis) result a change?
This editorially independent podcast is supported with advertising.
The Port Delivery System With Ranibizumab (Genentech) is under investigation for the treatment of wet AMD in the phase 3 ARCHWAY trial, data from which was shared at this year’s AAO Annual Meeting. Nancy Holekamp, MD, sits down with NRR to provide a primary analysis of the results of ARCHWAY and discusses safety outcomes.
This editorially independent podcast is supported with advertising.
New Retina Radio’s John Kitchens, MD, and Jorge Fortun, MD, introduce the premier episode of New Retina Radio Journal Club, a new series dedicated to reviewing the latest papers and how they relate to day to day clinical practice. In this episode, Dr. Fortun is joined by Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, to discuss two papers that address the role, or lack thereof, of anti-VEGF therapy in the treatment of neovascular age-related macular degeneration and geographic atrophy.
This editorially independent podcast is supported with advertising.
In this podcast, Prof. Bart Leroy (Belgium), Prof. Isabelle Audo (France) and Prof. Robert Maclaren (UK) discuss the management of patients with inherited retinal diseases (IRDs), from the initial identification of a patient with an IRD and referral to specialist center, through to the confirmation of a diagnosis using genotyping and the long-term implications for the patient of receiving that diagnosis. They discuss the current treatment landscape for patients with IRDs and outline future potential therapies on the horizon.
This editorially independent podcast is supported with advertising.
Arming patients with knowledge is key to fighting any disease. What happens when a confluence of factors create a breeding ground for an uneducated patient population? John W. Kitchens, MD (United States), is joined by Patricio Schlottmann, MD (Argentina), Nicole Eter, MD (Germany), and Adnan Tufail, MBBS, MD, FRCOphth (United Kingdom) to review tactics for educating patients and battling misinformation in the COVID-19 era.
This editorially independent podcast is supported with advertising.
The COVID-19 pandemic accelerated the use of telemedicine. How has this held up in retina now that we’ve had more than 6 months of experience under our belts? New Retina Radio host John Kitchens, MD, invites Judy E. Kim, MD; Byron Ladd, MD; and Carl D. Regillo, MD, to review how their practices have used (or not used) telemedicine during the pandemic. Also, Dr. Kitchens asks the panel how they’ve handled educating patients about the pandemic—and how they’ve tackled questions of misinformation.
This editorially independent podcast is supported with advertising.
Telemedicine has been put to the test during the COVID-19 pandemic. How is it holding up—and just how effective will it be going forward? John W. Kitchens, MD (United States), is joined by Francesco Boscia, MD (Italy); David Steel, MBBS, FRCOphth (United Kingdom); and Ramin Tadayoni, MD, PhD (France), to discuss how much telemedicine has delivered as promised.
This editorially independent podcast is supported with advertising.
The internal regulations governing academic institutions were tested during the COVID-19 surges of spring and summer. As we move into autumn, how effective have they been—and are any worth revisiting? New Retina Radio host John Kitchens, MD, reviews this topic with Dilraj Grewal, MD, from the Duke Eye Center; Adrienne Scott, MD, from the Wilmer Eye Institute; and Elliott Sohn, MD, from University of Iowa to gain a better understanding of how institutional safeguards kept patients and staff safe, and how they may have served as (sometimes necessary) roadblocks to getting practice back to pre-pandemic levels.
This editorially independent podcast is supported with advertising.
The disruptions to clinical and surgical workflows during the COVID-19 crisis are obvious. Less apparent are the downstream effects of adjustments to educational experiences. New Retina Radio host John Kitchens, MD, invites three leaders in academic retina—Sophie Bakri, MD, of the Mayo Clinic; Julia Haller, MD, of Wills Eye Hospital; and R.V. Paul Chan, MD, MSc, MBA, of the University of Illinois at Chicago—to discuss how training and selection of fellows has been altered during the COVID-19 pandemic, and to review the tactics their institutions have employed to mitigate the interference their programs have endured.
This editorially independent podcast is supported with advertising.
Approaches to treating retinitis pigmentosa have included prosthetic devices and gene therapy. What if there was an approach that could treat the nearly 2 million worldwide patients with disease? Anthony Joseph, MD, discusses jCell technology, which may work independently of a patient’s genetic subtype to promote photoreceptor survival in retinitis pigmentosa patients. What data from a phase 2b trial were used to evaluate the efficacy of jCell technology? How will the therapy be tested going forward? What safety concerns should clinicians be aware of? Dr. Joseph has some answers.
This editorially independent podcast is supported with advertising.
A COVID-19 resurgence seems increasingly likely as autumn and winter approach the United States, forcing people indoors and increasing transmission risk. What can retina clinicians learn from the spring and summers waves of COVID-19 infections that could be applied to the cooler months of 2020? John W. Kitchens, MD, invites Steve Charles, MD; Amy Schefler, MD; and Jayanth Sridhar, MD, to gameplan the future of retina clinics.
This editorially independent podcast is supported with advertising.
Retina’s ability to adjust to a new environment should be commended. Which of the technologies introduced during the COVID-19 era are stopgaps and which will be a permanent part of the treatment landscape? John W. Kitchens, MD (United States), is joined by María H. Berrocal, MD (United States); Jean-Francois Korobelnik, MD, PhD (France); and Manish Nagpal, MBBS, MS, FRCS (Edin) (India), to forecast the future of retina’s technologic milieu.
This editorially independent podcast is supported with advertising.
Treat-and-extend therapy is a common tactic employed by retina specialists for treating wet AMD patients. What new data will grow the body of information retina specialists already draw on when making decisions about treatment regimen? Michael Singer, MD, shares details from a retrospective review of patient data over a 2-year period during which treat-and-extend regimens were employed.
This editorially independent podcast is supported with advertising.
In the midst of the COVID-19 pandemic, medicine cannot forget about the raging opioid epidemic taking place in the United States. What role to retina specialists play in fueling the opioid crisis, and how has their behavior changed for the better over time? Yoshihiro Yonekawa, MD, shares his research about opioid prescribing rates among retina specialists, tracing the field’s behavior over time, and offering a window into the specialty’s role in the crisis.
This editorially independent podcast is supported with advertising.
The phase 2 LADDER study showed the Port Delivery System for ranibizumab was worthy of a phase 3 trial. Was the device able to deliver a continuous dose of therapy that was similar to what you’d find in monthly injection patients? Dilsher Dhoot, MD, reviews the pharmacokinetic data that researchers used to determine the rate of drug release and therapeutic benefit and previews the phase 3 ARCHWAY trial.
This editorially independent podcast is supported with advertising.
Protocols for clinical and surgical settings have been altered in the COVID-19 era. Which of those protocols are temporary, and which protocols will be a permanent part of practice? To answer this question, New Retina Radio host John W. Kitchens, MD, invites María Ana Castellanos-Martinez, MD (Mexico) and Matteo Forlini, MD (Italy) for a roundtable discussion on the future of retina care in the wake of COVID-19–related changes.
This editorially independent podcast is supported with advertising.
Conferences are an essential dynamic to the retina ecosystem that have been disrupted during the COVID-19 crisis. How will the field advance without in-person meetings? New Retina Radio host John W. Kitchens, MD, invites EURETINA General Secretary Anat Loewenstein, MD, and ASRS President Timothy G. Murray, MD, MBA, to discuss the future of in-person education, the evolving dynamics of physician-industry collaboration, and the solutions that retina societies have relied on to maintain retina’s camaraderie.
This editorially independent podcast is supported with advertising.
Safe and effective long-duration therapy in wet AMD treatment could be the solution to increasing patient adherence. Are we on the brink of a major breakthrough? Carl Danzig, MD, reviews the phase 2 STAIRWAY study, which evaluated the safety and efficacy of faricimab (Genentech/Roche) for the treatment of wet AMD, and previews the coming phase 3 trials TENAYA and LUCERNE.
This editorially independent podcast is supported with advertising.
Dry AMD research was a hot topic at this year's ARVO annual meeting. Could ethically sourced stem cells from human embryos provide a solution to this challenging disease? Chris Riemann, MD, shared data from an early phase trial that sought to understand the safety of RPE cells surgically implanted below the retina.
This editorially independent podcast is supported with advertising.
The ARVO Board of Trustees had only a few weeks to turn their massive, in-person meeting into a virtual symposium that highlighted the year's biggest advancements in ophthalmology research. Iris Rush, the Executive Director of ARVO, spoke to New Retina Radio about the experience, and spelled out what they learned that can be applied to future ARVO meetings.
This editorially independent podcast is supported with advertising.
In-person retina conferences are halted, but the flow of data isn't. In this episode of New Retina Radio, Jennifer Lim, MD, breaks down 100-week data from the PANORAMA trial, which she shared at the ARVO virtual meeting. Dr. Lim's presentation may help retina doctors make informed treatment decisions about long-term therapy for nonproliferative diabetic retinopathy.
This editorially independent podcast is supported with advertising.
National responses to the COVID-19 pandemic have varied. Will responses in the retina clinic look more homogenous than governments' actions have? NRR Guest Host María Berrocal, MD (United States), invites Hai Lu, MD (China), Virgilio Morales-Canton, MD (Mexico), and Martin Charles, MD (Argentina), to discuss how the global retina community will communicate, act, and respond in the months ahead.
This editorially independent podcast is supported with advertising.
Protocols have changed significantly during the COVID-19 pandemic. Which of those procedures are here to stay and which will disappear as the pandemic subsides? NRR host John Kitchens, MD, invites Murtaza "Moo" Adam, MD; David R.P. Almeida, MD, PhD, MBA; and Christina Weng, MD, MBA, to discuss which changes implemented in 2020 will be permanent fixtures in retina practice.
This editorially independent podcast is supported with advertising.
New Retina Radio checks in with different corners of the globe to hear how retina specialists are responding to changing conditions in their nations. NRR host Allen Ho, MD (United States), and guest host Ehab El-Rayes, MD, PhD (Egypt), invite Matteo Forlini, MD (Italy), and Monica Lövestam-Adrian, MD (Sweden), to share their tactics for providing optimal patient care in the wake of a global pandemic.
This editorially independent podcast is supported with advertising.
The COVID-19 crisis has forced retina specialists to implement a number of protocols-and wish for a number of technologies. Which of those will endure after the pandemic subsides and which are particular to the moment? NRR host John Kitchens, MD, is joined by Caroline Baumal, MD; María Berrocal, MD; and Judy Kim, MD, to discuss which practices will be rolled into modern protocols, which technologies on the horizon may have greater value in a post-COVID world, and how treatment decisions have (or have not) been adjusted to face today's unique challenges.
This editorially independent podcast is supported with advertising.
As the COVID-19 pandemic rages in some places and subsides in others, retina-focused societies from around the world must provide guidance to their members. How are different organizations doing so? Special guest host and president of the Retina World Congress Tarek Hassan, MD (United States), sits down with Asia-Pacific VitreoRetina Society leadership member Paisan Ruamviboonsuk, MD (Thailand), and Pan-American Association of Ophthalmology Immediate Past-President J. Fernando Arevalo, MD, PhD (United States), and Euretina General Secretary Anat Loewenstein, MD (Israel).
This editorially independent podcast is supported with advertising.
Telemedicine in retina has been pregnant with promise. Is it time to deliver? NRR host John Kitchens, MD, dives into this conversation with S.K. Steven Houston III, MD; John B. Miller, MD; and Ehsan Rahimy, MD, to understand telemedicine's viability and durability during and beyond the COVID-19 era, and to review proper coding tactics to ensure compliance.
This editorially independent podcast is supported with advertising.
The COVID-19 outbreak started months ago in Wuhan, China, but many parts of Asia are feeling the brunt of the pandemic now. How are retina specialists in various regions handling it? New Retina Radio hosts Allen C. Ho, MD, and R.V. Paul Chan, MD, MBA, check in with retina specialists Shunji Kusaka, MD, PhD (Japan); Manish Nagpal, MS, DO, FRCS(UK) (India); and Wei-Chi Wu, MD, PhD (Taiwan).
This editorially independent podcast is supported with advertising.
Can clinical trials go forward during the COVID-19 crisis? If so, how? And if not, then how do we proceed? NRR host John Kitchens, MD, and special co-moderator Namrata Saroj, OD, invite clinical trial veterans Jeffrey Heier, MD; Carl Regillo, MD; and Charles Wykoff, MD, PhD, to discuss the future of one of retina's most important components.
This editorially independent podcast is supported with advertising.
How will the COVID-19 crisis transform retina care in Europe? New Retina Radio asks these questions with Jordi Monés, MD, PhD (Spain), at the helm. He is joined by David H.W. Steel, MBBS, FRCOphth (United Kingdom); Murat Oncel, MD (Turkey); and Armin Wolf, MD, FEBO (Germany), to hear about the future of retina care in the wake of COVID-19.
This editorially independent podcast is supported with advertising.
Retina fellowships are one of the crown jewels of ophthalmology. But what happens to trainees during the COVID-19 crisis? NRR host John Kitchens, MD, is joined by attendings Sharon Fekrat, MD, from the Duke Eye Center; Thomas Albini, MD, from the Bascom Palmer Eye Institute; and Prithvi Mruthyunjaya, MD, MHS, from the Byers Eye Institute at Stanford University, to hash out the new realities of retina fellowship training.
This editorially independent podcast is supported with advertising.
New Retina Radio's global series continues as we check in on Latin America. Allen C. Ho, MD, and María H. Berrocal, MD, invite Lihteh Wu, MD (Costa Rica); Gustavo Hüning, MD, MBA (Brazil); and Maria Ana Martinez Castellanos, MD, to share their experiences with COVID-19.
This editorially independent podcast is supported with advertising.
What role do professional organizations play in the COVID-19 crisis? NRR host John Kitchens, MD, invites AAO CEO David W. Parke II, MD, and AAO Immediate Past President George Williams, MD, to the program to discuss how the Academy is helping shepherd ophthalmologists through the current situation. Also joining Dr. Kitchens are Timothy G. Murray, MD, MBA, president of the ASRS, and J. Michael Jumper, MD, ASRS Chair of Education and the COVID-19 Task Force, who discuss how retina's largest organization is guiding its members to success.
This editorially independent podcast is supported with advertising.
R.V. Paul Chan, MD, MSc, and Allen C. Ho, MD, host a panel comprised of Seung-Young Yu, MD (South Korea); Daniel Ting, MD, PhD (Singapore); and Paisan Ruamviboonsuk, MD (Thailand). The moderators and panel will discuss the evolving situation in Asia and how various medical systems have responded to the COVID-19 crisis.
This editorially independent podcast is supported with advertising.
John W. Kitchens, MD, joins Alan Ruby, MD, and Robert Foster, MD, to discuss the business of retina in the COVID-19 era, covering everything from the merits of applying for government loans to the effects of COVID-19 on private equity trends.
This editorially independent podcast is supported with advertising.
Allen C. Ho, MD, hears from Italian retina specialist Stanislao Rizzo, MD, Spanish retinal specialist Jordi Monés, MD, PhD, and French retinal specialist Ramin Tadayoni, MD, PhD, about the conditions in European medical centers during the COVID-19 crisis.
This editorially independent podcast is supported with advertising.
John Kitchens, MD, hosts George Williams, MD, from Associated Retina Consultants outside of Detroit; Gwen Cousins, MD, from Retina Associates New Orleans; and Lisa Olmos de Koo, MD, MBA, from the University of Washington in Seattle, to hear how COVID-19 outbreaks in their respective cities have changed retina practice-and the practice of medicine in general.
This editorially independent podcast is supported with advertising.
John Kitchens, MD, hosts Sunir Garg, MD; Nancy Holekamp, MD; and Rishi Singh, MD, to learn how each of their practices has been affected by the COVID-19 crisis. They discuss new patient protocols, staffing complications, and working with colleagues who are at risk for contracting COVID-19.
This editorially independent podcast is supported with advertising.
Gary Wörtz, MD, and Blake Williamson, MD, MPH, discuss COVID-19 transmission with Karl Stonecipher, MD, and Julie Schallhorn, MD, MS. Drs. Stonecipher and Schallhorn share tactics for protecting staff, family members, and physicians from contracting the virus, and urge listeners to remind their friends and family that this is not a drill.
This editorially independent podcast is supported with advertising.
The heterogeneous nature of uveitis makes it a challenging disease to treat. Phoebe Lin, MD, PhD, reviews common mistakes in uveitis management that an AAO panel found worthy of highlighting. And Steven Yeh, MD, discusses which emerging infectious diseases retina specialists need to know about-and what they can do when they encounter them.
This editorially independent podcast is supported with advertising.
Uveal melanoma carries a risk of metastasis, which may occur before the disease is even detected. Moreover, even when uveal melanoma is treated, there's a good chance that the radiation used during therapy will result in radiation retinopathy. Prithvi Mruthyunjaya, MD, MHS, reviews the state of uveal melanoma therapies in clinical trials and discusses how doctors might employ new tactics to prevent metastatic disease. Also, Amy Schefler, MD, outlines a trial examining how patients with radiation retinopathy respond to anti-VEGF therapy. How could this change the visual function of patients whose cancer treatments left them visually impaired?
This editorially independent podcast is supported with advertising.
Brolucizumab (Beovu, Novartis) was approved by the US FDA for the treatment of wet AMD. But how does it affect patients with polypoidal choroidal vasculopathy? Glenn Jaffe, MD, joins the podcast to discuss a substudy in the phase 3 HAWK trial that aimed to find out. Also, as the FDA reviews a new drug application for abicipar pegol (Allergan), what can we learn from the phase 3 trials CEDAR and SEQUOIA now that the 2-year data were released? Rahul Khurana, MD, details his presentation live from the BMC booth.
This editorially independent podcast is supported with advertising.
Diabetic retinopathy may be proliferative or nonproliferative, and patients may present with or without macular edema. And then there's the possibility that one patient's disease is VEGF-mediated whereas another's is not. With all of these factors, it's important to understand which therapeutic options work best for particular patients. Nathan Steinle, MD, reviews data from the BOULEVARD trial, a phase 2 study evaluating faricimab (Genentech/Roche) in patients with DME. And Rishi Singh, MD, parses the 52-week data from the PANORAMA trial, which evaluated the effect of aflibercept (Eylea, Regeneron) in approximately 400 patients with high-risk NPDR without DME.
This editorially independent podcast is supported with advertising.
This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again.
Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD, to tell the latest chapter of anti-VEGF's biography.
This editorially independent podcast is supported with advertising.
New Retina Radio continues its biography of anti-VEGF. John D. Pitcher III, MD, picks up the story where we left off: in a world where pegaptanib was the only intravitreal injection approved for treating wet AMD. But a deep dive into the literature and a few calculations on the back of a napkin are about to change retina practice forever. Guests in this episode include Bob Avery, MD; Dave Brown, MD; Anne Fung, MD; Jeffrey Heier, MD; Andrew Moshfeghi, MD, MBA; Kirk Packo, MD; and Philip Rosenfeld, MD, PhD. This editorially independent podcast is supported with advertising.
Practicing retina in the developing world means facing frustrating, unexpected, and sometimes dangerous circumstances. Don D'Amico, MD, R.V. Paul Chan, MD, and Pravin Dugel, MD, share their stories of engaging medical communities from Tanzania to Armenia and Vietnam to Nepal. This podcast is editorially independent.
Hawks have more than one fovea and a cornea that changes shape to sharpen focus on prey. Who knew? Well, one retina doctor did. James C. Major Jr, MD, PhD, joins us for an episode to review his early contributions to animal imaging. But the story is bigger than that. Dr. Major's journey illustrates that a marriage between two passions-in his case, the blossoming world of optical coherence tomography in the early 2000s and an ornithological hobby-can send a retina doctor down uncharted paths of scientific discovery. This podcast is editorially independent.
Many young retina specialists have always known retina as an anti-VEGF world. But how did this happen? John D. Pitcher III, MD, joins Scott and Ranna in studio to deliver the first part of the tale of anti-VEGF in retina, taking the story back to the 1970s to tell the story of the discovery of VEGF, the creation of pegaptanib, and the struggles that early anti-VEGF encountered in retina. There are a lot of guests for this one, but the major players for this episode are Tony Adamis, MD; Bob Avery, MD; Jeff Heier, MD; and Kirk Packo, MD. This editorially independent podcast is supported with advertising.
All retina specialists have an MD; not all retina specialists have another postgraduate degree. In this episode of New Retina Radio, we examine how and why those degrees were obtained by retina specialists-and if they were even worth the time. Featuring Derek Kunimoto, MD, JD; Paul Hahn, MD, PhD; David Almeida, MD, PhD, MBA; and Scott Walter, MD, MS. This podcast is editorially independent.
Finding a partner for your retina practice can be a lot like dating-you need to find someone whose values align with your values, who enhances your best qualities, and who doesn't make you pull your hair out. In this episode, New Retina Radio goes retro-think The Dating Game but (slightly) less corny. Featuring Geeta Lalwani, MD, and Charlie Mango, MD. This podcast is editorially independent.
Last episode, we heard from women at various stages in their careers about the unique nature of practicing retina as a woman. In part 2 of 2, they discuss the role of men in the development of women, the merits of joining groups like Women in Retina, and how experience shapes perception of how the industry treats female candidates. Featuring Julia Haller, MD; Anat Loewenstein, MD; Geeta Lalwani, MD; Jessica Randolph, MD; and Talisa de Carlo, MD. This podcast is editorially independent.
Practicing retina consumes your life. Add a pair of X chromosomes into the mix, and you face a very different set of circumstances. In the debut episode of New Retina Radio, we sit down with Julia Haller, MD; Anat Loewenstein, MD; Jessica Randolph, MD; and Talisa de Carlo, MD, to hear about the how women in retina operate-and how men factor into the equation. This podcast is editorially independent.